STAT

Opinion: Using CRISPR for the ‘smaller wins,’ like making chemotherapy less toxic

Big breakthroughs in cancer treatment are great. But don't overlook the value of smaller wins, which can be big ones for patients.

Although the phrase “war on cancer” was first uttered in 1971, the breakthroughs in biomedical research that have emerged during this decade have supercharged the fight. The introduction of CRISPR-Cas9 — the molecular scissors that can edit DNA — makes the idea of powerful new tools to treat and prevent cancer feel tantalizingly close.

Ambitious efforts to prevent or beat cancer are important, but we can’t overlook or undervalue the incremental breakthroughs that could quickly reach patients and improve lives. What if, for example, we used CRISPR to make chemotherapy a bit less terrible for patients suffering with cancer now? That’s

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About Amylyx Pulling Its ALS Drug, GLP-1 Drugs For Parkinson’s, And More
Amylyx Pharmaceuticals will take its ALS drug Relyvrio off the market in the U.S. and Canada, ending a multi-year saga for patients with the rare neurodegenerative disease.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About An OptumRx Contract, 340B Dispute Resolution, And More
Cardinal Health announced its pharmaceutical distribution contracts with UnitedHealth's OptumRx unit will not be renewed after they expire in June.
STAT1 min read
USDA Faulted For Disclosing Scant Information About Outbreaks Of H5N1 Avian Flu In Cattle
With 28 herds in eight states infected with H5N1 bird flu, scientists are calling on the U.S. to release more data to help them assess the risk.

Related Books & Audiobooks